← Back to Search

Polyphenol Supplement

Whole coffee cherry extract for Drug Effects (WCCE Trial)

Q: Does this research encompass those aged fifty or above?

This trial is accepting patients from the age of 40 to 65 years.

Q: What is the current enrolment of participants in this clinical research?

Affirmative. According to information published on clinicaltrials.gov, this scientific investigation is currently recruiting applicants. It was initially advertised on February 1st 2022 and the details were revised as recently as March 11th 2022. 200 patients have been requested from a single medical institution.

Q: Is this research opportunity accessible to participants currently?

Accurately, the clinicaltrials.gov website indicates that recruitment for this study is ongoing; having first been posted on February 1st 2022 and most recently updated March 11th 2022. 200 individuals are needed from a single site.

Q: Could I be enrolled in this medical experiment?

To be eligible to participate in this study, patients must demonstrate a response to prior medications and fall within the age bracket of 40 and 65. This trial will ultimately involve 200 participants.

Q: What primary goals are researchers seeking to achieve by conducting this investigation?

As stated by the clinical trial sponsor, VDF FutureCeuticals Inc., the primary outcome being assessed is Behavioral Measures - Change in Flanker Task Reaction Time. This dataset will be collected over a four-week period. Secondary outcomes to be explored include <a href="https://www.withpower.com/clinical-trials/sleep">sleep</a> hygiene (via questionnaire), daily mood (on a 0-100 scale where 0 = worst and 100 = best) and hours of sleep per night for <a href="https://www.withpower.com/clinical-trials/all">all</a> 28 days of the study.

N/A

Waitlist Available

Research Sponsored by Auburn University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up daily for the duration of the study (approximately 28 days)

Awards & highlights

WCCE Trial Summary

This trial will study the effects of a coffee cherry extract on measures of cognition.

WCCE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ daily for the duration of the study (approximately 28 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~daily for the duration of the study (approximately 28 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and daily for the duration of the study (approximately 28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Behavioral Measures - Change in Face in the Crowd Time

Behavioral Measures - Change in Face-Name Reaction Time

Behavioral Measures - Change in Flanker Task Reaction Time

+5 more

Secondary outcome measures

Daily Self-reported Mood

Daily Self-reported Sleep

Weekly Self-reported Mood

+1 more

Other outcome measures

Compliance

WCCE Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Whole coffee cherry extractActive Control1 Intervention

Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (<2%; <4mg) levels of caffeine. The only content of the supplement is WCCE - there are no excipients, binders, or flow agents, nor are there any other materials. The coffee cherry is subjected to a food-grade water ethanol extraction; thus, after extraction, only 100% coffee-based components remain. 200mg of WCCE will be administered daily for 28 days.

Group II: PlaceboPlacebo Group1 Intervention

The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

VDF FutureCeuticals Inc.Industry Sponsor

4 Previous Clinical Trials

117 Total Patients Enrolled

Auburn UniversityLead Sponsor

72 Previous Clinical Trials

14,082 Total Patients Enrolled

Media Library

Whole coffee cherry extract (Polyphenol Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT04986956 — N/A

Drug Effects Research Study Groups: Placebo, Whole coffee cherry extract

Drug Effects Clinical Trial 2023: Whole coffee cherry extract Highlights & Side Effects. Trial Name: NCT04986956 — N/A

Whole coffee cherry extract (Polyphenol Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04986956 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research encompass those aged fifty or above?

"This trial is accepting patients from the age of 40 to 65 years."

Answered by AI

What is the current enrolment of participants in this clinical research?

"Affirmative. According to information published on clinicaltrials.gov, this scientific investigation is currently recruiting applicants. It was initially advertised on February 1st 2022 and the details were revised as recently as March 11th 2022. 200 patients have been requested from a single medical institution."

Answered by AI

Is this research opportunity accessible to participants currently?

"Accurately, the clinicaltrials.gov website indicates that recruitment for this study is ongoing; having first been posted on February 1st 2022 and most recently updated March 11th 2022. 200 individuals are needed from a single site."

Answered by AI

Could I be enrolled in this medical experiment?

"To be eligible to participate in this study, patients must demonstrate a response to prior medications and fall within the age bracket of 40 and 65. This trial will ultimately involve 200 participants."

Answered by AI

What primary goals are researchers seeking to achieve by conducting this investigation?

"As stated by the clinical trial sponsor, VDF FutureCeuticals Inc., the primary outcome being assessed is Behavioral Measures - Change in Flanker Task Reaction Time. This dataset will be collected over a four-week period. Secondary outcomes to be explored include sleep hygiene (via questionnaire), daily mood (on a 0-100 scale where 0 = worst and 100 = best) and hours of sleep per night for all 28 days of the study."

Answered by AI